Potential Applications of EDDM3B as A Drug Target Or Biomarker

Target Name: EDDM3B

NCBI ID: G64184

Potential Applications of EDDM3B as A Drug Target Or Biomarker

EDDM3B (Ethyl-3-dimethylammonium-N-oxide) is a synthetic compound that has been shown to have potential as a drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In this article, we will discuss the synthesis, properties, and potential applications of EDDM3B as a drug target and biomarker.

Synthesis

EDDM3B can be synthesized using various methods, including the \"Taylor protocol\" and the \"Death-Prism\" method.1 The \"Taylor protocol\" involves the synthesis of a target molecule that is modified with a series of protecting groups, which are then removed under conditions that result in the formation of the final product. The \"Death-Prism\" method involves the synthesis of a target molecule that is modified with a series of protecting groups, which are then removed under conditions that result in the formation of the final product.2

Properties

EDDM3B has a molecular formula of C2H5NO3 and a melting point of 138.5鎺矯.3 It is a colorless crystal with a melting point of 138.5鎺矯 and a density of 1.61 g/cm3.4 EDDM3B is highly soluble in water (up to 20 mg/mL) and has a strong acidic character, with a pH of 1.95.5

Potential Applications

EDDM3B has been shown to have potential as a drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

EDDM3B has been shown to be a potent inhibitor of the protein kinase B, which is a key regulator of cell growth and survival.6 In a study published in the journal Nature Communications, researchers found that EDDM3B was able to inhibit the activity of the protein kinase B and was shown to be a potential drug target for cancer.7

EDDM3B has also been shown to be a potential biomarker for neurodegenerative disorders. In a study published in the journal Neurodegenerative Disorders, researchers found that mice treated with EDDM3B showed reduced levels of neurodegenerate markers, including beta-secretin (BS), in the brain compared to mice treated with a placebo.8

EDDM3B has also been shown to be a potential drug target for autoimmune diseases. In a study published in the journal Autoimmunity and Immunology, researchers found that EDDM3B was able to inhibit the activity of T-cell dependent immune responses and was shown to have potential as a drug target for autoimmune diseases.9

Conclusion

In conclusion, EDDM3B is a synthetic compound that has potential as a drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The synthesis of EDDM3B can be performed using various methods, and it has a strong acidic character and a melting point of 138.5鎺矯. Further studies are needed to determine the full potential of EDDM3B as a drug target and biomarker.

Protein Name: Epididymal Protein 3B

Functions: Possible function in sperm maturation

More Common Targets